article · AAPS PharmSciTech
Abstract Colorectal cancer (CRC) is a major cause of cancer-related death. Resveratrol (RES), despite its promising anti-inflammatory, antioxidant, and anticancer properties, suffers from poor solubility, low bioavailability, and limited tumor accumulation. Accordingly, eight RES-loaded bilosomes were prepared and characterized. Optimization was performed using a desirability study based on the observed colloidal properties. The selected formulation was radiolabeled with iodine-131 and assessed for radiolabeling efficiency and stability. In-vitro cytotoxicity was evaluated against HT- 29 and LS174T CRC cell lines. Biodistribution studies in tumor-bearing mice were also assessed. Bilosomes displayed PS (93.08 to 340.00 nm), negative charges (-27.50 to -51.80 mV), EE% (73.45—96.35%), and a sustained release over a 24-h period. Optimization revealed formulation with PS (163.8 nm), PDI (0.41), EE% (93.80%) and ZP (− 51.8 mV). Radiolabeling efficiency was 93.23 ± 2.15% and was stable for 2 h. In tumor-bearing mice, the tumor uptake of 131 I-RES bilosomes was 4.34-fold compared to 131 I-RES solution, indicating enhanced tumor accumulation and selectivity, likely driven by enhanced permeability and retention-mediated passive targeting. Bilosomes significantly enhanced cytotoxicity, reducing IC₅₀ values ~ fourfold in LS174T and ~ sixfold in HT-29 cells versus free RES. The pharmacokinetic behavior revealed a significantly higher C max for bilosomes relative to the solution. This study marks the first integration of 131 I-radiotracking with RES-loaded bilosomes, enabling precise measurement of biodistribution and tumor targeting. The approach established a theranostic framework that combined enhanced drug delivery with real-time tracking. Mechanistically, it improved RES accumulation in CRC, highlighting its potential but also underscoring the need for further preclinical research. Graphical Abstract
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1208/s12249-026-03441-3
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.